TO THE EDITOR-The Veterans Health Administration (VHA) is the single largest provider of hepatitis C virus (HCV) care within the United States, with a 5.4% seroprevalence rate for all veterans, which is 3-fold greater than that of the general US population [1] . With this high HCV prevalence and known subsequent complications of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and increased mortality [2] , VHA issued Directive 2013-1300.01, committing VHA to expand access to treatment and improve prevention, diagnosis, care, and treatment of viral hepatitis across its healthcare system. Sofosbuvir was approved for HCV treatment in December 2013 and was followed by simeprevir, sofosbuvirledipasvir, and ombitasvir-paritaprevirritonavir plus dasabuvir in 2014; all have been added to the VHA National Formulary. These direct-acting agents (DAAs) allow for interferon-sparing oral therapy to effectively treat HCV infection. We assessed the rates of HCV treatment at the VA Medical Center in Washington, D.C. (DC-VAMC), before and after the availability of interferon-sparing oral DAA regimens.
After approval by the Institutional Review Board and the Research and Development Committee at the DC-VAMC, a retrospective review of all HCV-infected patients in care at the DC-VAMC from 1 January 2008 to 31 March 2015 was conducted using summary data on pharmacy utilization from the HCV Clinical Case Registry [3] . Patients were stratified by the presence/absence of human immunodeficiency virus (HIV) infection. Receipt of any HCV treatment was assessed Table 1 , interferon-based regimens were used as standard of care during 2008-2013 and were replaced during 2014 as interferon-sparing DAA regimens became available. Sofosbuvirledipasvir with or without ribavirin accounted for 87% of all HCV regimens since November 2014.
We demonstrated a striking increase in HCV treatment during 2014 through 31 March 2015 with the availability of interferon-sparing oral DAA regimens at DC-VAMC, with a 2.3-fold increase for all HCV-infected patients. This keenly impacts the DC-VAMC, given our HCV prevalence at 13% among patients in care and cirrhosis at 15% of HCV-infected patients during 2008-2013 [4] . Local data from our DC-VAMC depicted the rate of HCV in our HIV-coinfected patients to be as high as 25% during 2011-2014 [5] . Our findings present an optimistic beginning to the realization of effective interferonsparing DAA regimens to broaden treatment for HCV-infected veterans. 
